{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T15:45:04Z","timestamp":1782747904845,"version":"3.54.5"},"reference-count":31,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jtct.2026.03.015","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T16:20:36Z","timestamp":1773505236000},"page":"854.e1-854.e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ferritin as a Pre-Transplant Biomarker for Post-Transplant Outcomes in Allogeneic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8355-433X","authenticated-orcid":false,"given":"Sergio","family":"Rodriguez-Rodriguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0522-5256","authenticated-orcid":false,"given":"Caden","family":"Chiarello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihar","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0520-4312","authenticated-orcid":false,"given":"Mats","family":"Remberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eshrak","family":"Al-Shaibani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommy","family":"Alfaro Moya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9251-3609","authenticated-orcid":false,"given":"Arjun Datt","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Pasic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auro","family":"Viswabandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotios V.","family":"Michelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis Dong Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4786-5699","authenticated-orcid":false,"given":"Rajat","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2163-6644","authenticated-orcid":false,"given":"Jonas","family":"Mattsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3748-3117","authenticated-orcid":false,"given":"Igor","family":"Novitzky-Basso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jtct.2026.03.015_bib0001","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/bmt.2008.262","article-title":"Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation","volume":"42","author":"Pullarkat","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2026.03.015_bib0002","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1080\/10428190903144659","article-title":"Iron overload, hematopoietic cell transplantation, and graft-versus-host disease","volume":"50","author":"Joachim Deeg","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.jtct.2026.03.015_bib0003","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1038\/s41409-021-01244-7","article-title":"Iron overload in the HCT patient: a review","volume":"56","author":"Tenneti","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2026.03.015_bib0004","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.bbmt.2014.04.024","article-title":"Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis","volume":"20","author":"Armand","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2026.03.015_bib0005","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0891-5849(96)00497-2","article-title":"Nontransferrin-bound iron in serum of patients receiving bone marrow transplants","volume":"22","author":"D\u00fcrken","year":"1997","journal-title":"Free Radic Biol Med"},{"issue":"4","key":"10.1016\/j.jtct.2026.03.015_bib0006","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000355192","article-title":"Assessment of labile plasma iron in patients who undergo hematopoietic stem cell transplantation","volume":"131","author":"Naoum","year":"2014","journal-title":"Acta Haematol"},{"issue":"11","key":"10.1016\/j.jtct.2026.03.015_bib0007","first-page":"2324","article-title":"Non-transferrin-bound iron and oxidative stress during allogeneic hemopoietic stem cell transplantation in patients with or without iron overload","volume":"24","author":"Baronciani","year":"2018","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"4","key":"10.1016\/j.jtct.2026.03.015_bib0008","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.2023022500","article-title":"How I manage iron overload in the hematopoietic cell transplantation setting","volume":"145","author":"Angelucci","year":"2025","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2026.03.015_bib0009","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1016\/S2352-3026(18)30036-X","article-title":"Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial","volume":"5","author":"Wermke","year":"2018","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.015_bib0010","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.0006-341X.2005.030814.x","article-title":"Survival model predictive accuracy and ROC curves","volume":"61","author":"Heagerty","year":"2005","journal-title":"Biometrics"},{"issue":"3","key":"10.1016\/j.jtct.2026.03.015_bib0011","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.015_bib0012","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"19","key":"10.1016\/j.jtct.2026.03.015_bib0013","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood.2019000956","article-title":"How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation","volume":"135","author":"Einsele","year":"2020","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2026.03.015_bib0014","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3390\/v16081294","article-title":"EBV reactivation and disease in allogeneic hematopoietic stem cell transplant (HSCT) recipients and its impact on HSCT outcomes","volume":"16","author":"Law","year":"2024","journal-title":"Viruses"},{"issue":"10","key":"10.1016\/j.jtct.2026.03.015_bib0015","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1182\/blood-2006-10-054924","article-title":"Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation","volume":"109","author":"Armand","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.03.015_bib0016","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1365-2141.2009.07774.x","article-title":"Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation","volume":"146","author":"Mahindra","year":"2009","journal-title":"Br J Haematol"},{"issue":"27","key":"10.1016\/j.jtct.2026.03.015_bib0017","article-title":"Effect of pre-transplantation serum ferritin on outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"97","author":"Yan","year":"2018","journal-title":"Medicine (United States)"},{"issue":"7","key":"10.1016\/j.jtct.2026.03.015_bib0019","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1084\/jem.20042433","article-title":"TIM-2 is expressed on B cells and in liver and kidney and is a receptor for H-ferritin endocytosis","volume":"202","author":"Chen","year":"2005","journal-title":"J Exp Med"},{"issue":"9","key":"10.1016\/j.jtct.2026.03.015_bib0020","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1182\/blood.V99.9.3326","article-title":"Heavy chain ferritin activates regulatory T cells by induction of changes in dendritic cells","volume":"99","author":"Gray","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.03.015_bib0021","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood.V83.3.737.737","article-title":"H- and L-rich ferritins suppress antibody production, but not proliferation, of human B lymphocytes in vitro","volume":"83","author":"Morikawa","year":"1994","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.03.015_bib0022","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1365-2141.2009.07774.x","article-title":"Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation","volume":"146","author":"Mahindra","year":"2009","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.jtct.2026.03.015_bib0023","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s12032-010-9496-1","article-title":"Hyperferritinemia is associated with low incidence of graft versus host disease, high relapse rate, and impaired survival in patients with blood disorders receiving allogeneic hematopoietic stem cell grafts","volume":"28","author":"Wahlin","year":"2011","journal-title":"Med Oncol"},{"key":"10.1016\/j.jtct.2026.03.015_bib0024","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3389\/fimmu.2020.00586","article-title":"Association of serum ferritin levels before start of conditioning with mortality after alloSCT \u2013 a prospective, non-interventional study of the EBMT Transplant Complications Working Party","volume":"11","author":"Penack","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.015_bib0025","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2019.030","article-title":"Iron toxicity and hemopoietic cell transplantation: time to change the paradigm","volume":"11","author":"Pilo","year":"2019","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.03.015_bib0026","first-page":"4442","article-title":"Iron overload decreases engraftment of mice receiving allogeneic or syngeneic bone marrow transplant","volume":"130","author":"Tang","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.03.015_bib0027","doi-asserted-by":"crossref","DOI":"10.1038\/srep10181","article-title":"ROS-mediated iron overload injures the hematopoiesis of bone marrow by damaging hematopoietic stem\/progenitor cells in mice","volume":"5","author":"Chai","year":"2015","journal-title":"Sci Rep"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.03.015_bib0028","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood-2022-167300","article-title":"Iron overload and iron-induced microbiome changes may affect lymphoid levels post bone marrow transplant and graft-versus-host disease survival in mice","volume":"140","author":"Qiu","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2026.03.015_bib0029","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/ejh.12309","article-title":"The bone marrow hematopoietic microenvironment is impaired in iron-overloaded mice","volume":"93","author":"Okabe","year":"2014","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.015_bib0030","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41392-024-01969-z","article-title":"Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects","volume":"9","author":"Ru","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.015_bib0031","doi-asserted-by":"crossref","first-page":"42.e1","DOI":"10.1016\/j.jtct.2022.10.002","article-title":"Iron chelation with deferasirox suppresses the appearance of labile plasma iron during conditioning chemotherapy prior to allogeneic stem cell transplantation","volume":"29","author":"Essmann","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2026.03.015_bib0032","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41375-023-01847-7","article-title":"Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)","volume":"37","author":"Badar","year":"2023","journal-title":"Leukemia"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726002228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726002228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:58:38Z","timestamp":1782745118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726002228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2666636726002228"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.03.015","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ferritin as a Pre-Transplant Biomarker for Post-Transplant Outcomes in Allogeneic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}